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ess: p.j.barnes@imperiSummary Asthma is now the commonest chronic disease in industrialised
countries and its prevalence is rising throughout the world. However, despite the
availability of very effective treatments many patients with asthma have poorly
controlled symptoms and frequent exacerbations, some of which require hospital
admission. Important factors contributing to poor asthma control are failure to
recognise asthma as a diagnosis, non-implementation of asthma management
guidelines and patient non-compliance with therapy. The guidelines themselves have
many inherent limitations. Chief among these is that the evidence upon which they
are based may be misleading. The evidence used to support recommendations in
guidelines is derived from double-blind, placebo-controlled studies in very carefully
selected patients who are usually compliant with therapy and instructed in the use
of inhalers. In the ‘real world’ things are very different and patients frequently fail
to understand how to use their therapy and are often non-compliant. Reasons for
non-compliance are complex and include complicated drug and dosing regimens and
inability to use inhaler devices correctly; particularly pressurised metered dose
inhalers (pMDIs) due to difficulty co-ordinating device activation and inhalation. Dry
powder inhalers (DPIs) preclude the need to co-ordinate inspiration with activation,
are easy and convenient to use and are environmentally friendly. There is no doubt
that the type of inhaler is just as important as the class of drug in the long-term
management of asthma. Improvements in inhaled drug delivery will continue to be
important in improving asthma management.
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The size of the asthma problem remains an
enormous one. The incidence of asthma continues
to rise throughout the world and has been
estimated to have approximately doubled over
the last 10 years,1,2 with the highest incidence
occurring in children, and particularly in the
youngest age groups.3,4 Furthermore, studies fromed.
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increase in asthma prevalence worldwide of 5–6%,
with asthma affecting 8–10% of children and 3–5%
of the adult population. Worryingly, there is still a
tendency to under-diagnose asthma, and conse-
quently underestimate the true prevalence of the
disease.5 Although asthma is still a relatively
infrequent cause of death, the rates of death from
asthma have risen in many countries in Europe, as
well as in Canada and the United States, but have
tended to decrease since 1998, perhaps due to
better management.6
We now know more about asthma than ever
before. It is a highly complex inflammatory disease
of the airways in which many cells and cellular
elements play a role, such as eosinophils, mast
cells, T-lymphocytes, macrophages, dendritic cells,
neutrophils and epithelial cells. These cells can
influence airway function through secretion of
mediators that act either directly on the airway
or indirectly through neural mechanisms.7 Cell-
derived mediators can influence airway smooth
muscle tone, modulate vascular permeability, acti-
vate neurons, stimulate mucus secretion and pro-
duce characteristic structural changes in the airway.
Structural changes include basement membrane
thickening, hypertrophy and hyperplasia of airway
smooth muscle, increases in goblet cell number,
enlargement of sub-mucous glands and remodelling
of the airway connective tissue.7,8 In susceptible
individuals these inflammatory changes result in the
well known signs and symptoms of asthma such as
wheezing, breathlessness, chest tightness and cough,
which are usually associated with widespread but
variable airflow obstruction that is often reversible
either spontaneously or with treatment.
Inhaled corticosteroids (ICSs) are the cornerstone
of modern asthma treatment. They control the
underlying airway inflammation in asthma by
inhibiting many aspects of the inflammatory pro-
cess, such as inhibiting the release of inflammatory
mediators and cytokines from a wide range of
inflammatory cells, reducing the expression of
adhesion molecules, reducing the survival of
inflammatory cells and increasing the synthesis of
anti-inflammatory proteins.9 Additionally, corticos-
teroids can increase the expression of b2-adreno-
ceptors10,11 and decrease the transcription of genes
coding for inflammatory receptors.
The aim of the present article was to review the
Global INitiative for Asthma (GINA) guidelines on
what constitutes asthma control, assess the current
status of asthma control and discuss the many
reasons why asthma, despite many pharmacological
and technological advancements, remains a poorly
controlled disease.Asthma control
Both national and international asthma manage-
ment guidelines are now widely available. Their
principle aim is to achieve control of the disease,
but what exactly constitutes asthma control?
According to the GINA guidelines12 asthma is
controlled if patients have: minimal chronic symp-
toms (including nocturnal symptoms); minimal or
infrequent exacerbations of their asthma; no
emergency hospital visits; minimal (ideally no)
use of as needed b2-agonists; no limitation to their
activity levels (including exercise); peak expiratory
flow rate (PEF) circadian variationo20%; near
normal PEF and; minimal (or no) adverse effects
from medication. These guidelines are updated
every year ensuring that they are always up to date,
so providing the best possible advice on asthma
management. The premise of the GINA approach to
therapy is to achieve control of asthma with the least
possible medication. As asthma severity increases
the dose of ICSs are stepped up and other classes of
drugs are added, particularly long-acting b2-agonists
(LABAs). Once control of asthma has been achieved
and maintained for at least three months, a gradual
reduction of the maintenance therapy should be
tried in order to identify the minimum therapy
needed to maintain control.
However, despite the implementation of asthma
management guidelines around the world, and the
availability of highly effective medication to combat
asthma symptoms and the underlying inflammatory
component of the disease, asthma remains poorly
controlled. A survey by Rabe and colleagues13
showed that of 2803 asthmatic patients in the
Asthma Insights and Reality in Europe (AIRE) study,
46% reported daytime symptoms and 30% reported
asthma-related sleep disturbances, at least once a
week. Additionally, in the previous 12 months, 25% of
patients reported an unscheduled urgent care visit,
10% reported one or more emergency room visits, 7%
reported overnight hospitalisation due to asthma and
17% reported taking time off work due to their
asthma symptoms.13 In the US the situation was even
worse (Fig. 1).13
This lack of control may be due to the fact that
patients are not being prescribed the recommend
medication, and if they are, they are not taking it.
The same study by Rabe and colleagues13 showed,
not surprisingly, that patients with mild asthma
used short-acting b2-agonists (SABAs) more than
ICSs. But, what is shocking is the fact that this same
treatment pattern was found in moderate asthma
and even in severe asthma, where less than one-
third of patients were taking ICSs (Fig. 2). This
statistic is extremely worrying, bearing in mind
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Figure 2 Short-acting b2-agonist: inhaled corticosteroid
ratio in patients with mild intermittent, mild-persistent,
moderate-persistent and severe asthma. Reprinted with
permission from Rabe and colleagues.13
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Figure 3 Asthma control in general practice: asthma
control and expectations (ACE study). Reprinted with
permission from Gruffydd-Jones.14
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Figure 1 Asthma remains a poorly controlled disease
both in Europe and the US. Reprinted with permission
from Rabe and colleagues.13
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patients. Patients attending their general practi-
tioner are also poorly controlled. A study by
Gruffydd-Jones14 showed that a high proportion of
patients (approximately 50%) with typical symp-
toms of asthma complained of wheezing, chest
tightness, cough and breathlessness (Fig. 3), which
significantly impacted on their life style and
activities (Fig. 4). Even patients who felt well were
symptomatic, showing that patients underestimate
their own symptoms and provide evidence that
asthma control may be even worse than previously
thought (Fig. 3). All aspects of life style were
affected including sleep, playing sport, going up
and down stairs, walking, socialising, playing with
children, going to work and sex life (Fig. 4). Bearing
in mind the degree of life style restrictions these
patients were experiencing, it was very surprising
that few of them discussed it with their doctor orspecialist nurse (Fig. 4).14 These results show that
poor control of asthma is a huge unrecognised
problem.Why is asthma poorly controlled?
Asthma management guidelines provide recom-
mendations for the optimal control of asthma. It
follows that one reason why asthma remains poorly
controlled may be that the guidelines are not being
implemented. Not only are physicians and patients
not adhering to asthma management guidelines,
but the guidelines themselves suffer from inherent
limitations. The generic nature of the guidelines is
an advantage on the one hand, but they cannot
take account of individual differences in response
to treatment and severity of side effects, neither
can they take account of the availability and/or
cost of pharmacological treatments in different
countries. Even without this information the guide-
lines are long which may not be conducive to rapid
understanding and incorporation into busy treat-
ment schedules. Although the guideline recommen-
dations are based on the best available scientific
evidence, including randomised controlled trials,
systematic reviews and meta-analyses, each of
these types of study have disadvantages associated
with them. The clinical studies usually have a
double-blind, placebo-controlled design and in-
clude very carefully selected patients who are
usually compliant with therapy and instructed in
the use of inhalers. In the ‘real world’ things are
very different and patients frequently fail to
understand how to use their therapy and are often
non-compliant. The current lack of asthma control
as reported by patients in the AIRE study13 partly
reflects the extent to which guidelines are not
being implemented.
The GINA guidelines recognise patient non-
compliance with therapy as a major reason why
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Figure 4 Restrictions on lifestyle in asthma: Asthma Control and Expectations (ACE study). Reprinted with permission
from Gruffydd-Jones.14
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compliance are complex and may be split into drug
and non-drug factors. Drug factors include: diffi-
culty using the inhaler device; complicated treat-
ment regimens; side effects of treatment; cost; the
fact that people do not like taking treatment; or
that the treatment is not readily available. Non-
drug factors are also barriers to compliance and
include such issues as: not understanding the
instructions; worrying about side effects; not
trusting the doctor; not being supervised taking
mediation so compliance is never checked; and
anger about being ill. There are also cultural issues
such as patients do not like being labelled with the
disease, they may forget to take the treatment and
there may be religious or ethical difficulties.
It is essential that when a given inhaled therapy
is prescribed to the patient that thought is given to
the inhalation device that delivers the drug to the
lung. In order to successfully deliver drug to the
lungs patients need to both understand how to
deliver the drug and need to be comfortable with
the delivery device. Inability to correctly use
inhaler devices is a major reason for non-compli-
ance with therapy. Pressurised metered dose
inhalers (pMDIs) are the most frequently prescribed
inhaler device but most patients cannot use them
effectively.15,16 Misuse of pMDIs, which is mainly
due to poor co-ordination between inhaler activa-
tion and inhalation, is frequent and associated with
poorer asthma control in ICS-treated patients.17
Dry powder inhalers (DPIs) have several advantages
over MDIs. They are breath-activated, easy and
convenient to use and environmentally friendly.
In summary, asthma management can be sum-
marised as a triangular relationship between thepatient, drug treatment and delivery device, with
each of these components interacting with the
other (Fig. 5). Asthma management guidelines
recommend the appropriate drug treatment for
patients based upon the severity of their disease.
The choice of delivery device is equally as
important as choice of therapeutic agent as the
amount of drug delivered to the lungs differs from
device to device. Device choice should also be
governed by patient choice as well as ease of use
and consistency of drug release which all have
implications for patient compliance. However,
patients are frequently non-compliant with their
therapy due in part to non-implementation and
non-adherence to asthma management guidelines
and also to misuse of inhaler devices.Conclusions
There are now several other delivery devices
besides pMDIs on the market, including breath-
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much easier for patients to use. These devices
require less instruction, are easier to use and
deliver drug efficiently which results in better lung
deposition of the inhaled drug. More ‘real world’
studies are needed in which patients are not
selected according to strict inclusion or exclusion
criteria, but reflect the range of patients normally
seen in clinical practice. ‘‘N of 1’’ studies are also
useful for determining how individual patients
respond to different treatments and this might
include different drugs as well as different types of
inhaler. There is no doubt that the type of inhaler is
just as important as the class of drug in the long-
term management of asthma in adults and children.
Although there are several new treatments for
asthma, which may be given orally (more specific
drugs) or via injection (monoclonal antibodies), it is
unlikely that these will be as effective as ICSs or
LABAs, so that inhaled therapy is likely to remain
predominant in the future. Improvements in in-
haled drug delivery will therefore continue to be
paramount in improving asthma management.References
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